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Abstract
Duchenne muscular dystrophy (DMD) is a lethal inherited muscle disorder. Pathological characteristics of DMD skeletal muscles include,
among others, abnormal Ca2 homeostasis and cell signalling. Here, in the mdx mouse model of DMD, we demonstrate significant P2X7
receptor abnormalities in isolated primary muscle cells and cell lines and in dystrophic muscles in vivo. P2X7 mRNA expression in dys-
trophic muscles was significantly up-regulated but without alterations of specific splice variant patterns. P2X7 protein was also up-reg-
ulated and this was associated with altered function of P2X7 receptors producing increased responsiveness of cytoplasmic Ca2 and
extracellular signal-regulated kinase (ERK) phosphorylation to purinergic stimulation and altered sensitivity to NAD. Ca2 influx and ERK
signalling were stimulated by ATP and BzATP, inhibited by specific P2X7 antagonists and insensitive to ivermectin, confirming P2X7
receptor involvement. Despite the presence of pannexin-1, prolonged P2X7 activation did not trigger cell permeabilization to 
propidium iodide or Lucifer yellow. In dystrophic mice, in vivo treatment with the P2X7 antagonist Coomassie Brilliant Blue reduced 
the number of degeneration–regeneration cycles in mdx skeletal muscles. Altered P2X7 expression and function is thus an important
feature in dystrophic mdx muscle and treatments aiming to inhibit P2X7 receptor might slow the progression of this disease.
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Introduction
Duchenne muscular dystrophy (DMD) is the second most com-
mon inherited disorder in man, and invariably leads to severe dis-
ability and premature death of young adults. This disease is
caused by mutations of the DMD gene resulting in the absence or
abnormalities of dystrophin. This protein, together with the dys-
trophin-associated protein complex, has a role in strengthening
the sarcolemma during contractile activity [1]. However, additional
pathogenic mechanisms are also involved. Intracellular free
 calcium [Ca2]i is raised in the sub-sarcolemmal region of
 dystrophic muscle, which cannot be explained by membrane rup-
tures alone [2].
We have previously shown that dystrophin appears to have a
function in controlling purinergic responses. In dystrophic (mdx)
mouse myoblasts, a purinergic phenotype arises in which expo-
sure to extracellular ATP triggers an increase in cytosolic free cal-
cium [Ca2]c caused primarily by activation of P2X7 receptors
[3]. This receptor is an ATP-gated ion channel permeable to small
cations, including Ca2, and its expression and/or function are
up-regulated by inflammatory mediators and by ATP itself. The
P2X7 receptor is therefore considered a ‘danger’ sensor, detect-
ing ATP released where tissue damage occurs [4]. The intracellu-
lar ATP content of muscles is high and ATP, released in small
amounts in response to physiological muscle activity, acts
through purinergic receptors to modulate skeletal muscle plastic-
ity [5]. In DMD, due to the fragility of myofibres, ATP is released
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in very large amounts into the extracellular space. These high
concentrations of ATP, especially if acting on an altered receptor,
could contribute to DMD pathology.
In this study, we show that P2X7 receptor expression and func-
tion are significantly altered in mouse dystrophic myoblasts and
myotubes in vitro and ex vivo and also in mdx muscle in vivo.
Pharmacological inhibition of this receptor in mdx mice in vivo
resulted in a significantly lower number of revertant fibres in
skeletal muscles, where such suppression is indicating a reduced
number of degeneration–regeneration cycles in treated animals
and used as one of the histological indicators for the assessment
of therapeutic effects [6]. These data suggest that treatment with
P2X7 antagonists may retard the dystrophic process.
Materials and methods
Animals
C57BL10 and mdx male mice were used in accordance with approvals 
of the institutional Ethical Review Board and the UK Home Office. Mice
(3–9 per group) received 125 mg/kg b.w. Coomassie Brilliant Blue G 250
(Sigma-Aldrich, Gillingham, UK) i.p., in sterile saline, every three days from
3 to 14 weeks of age. Control mice received the same volume of saline
solution. At 16 weeks, mice were killed and organs immediately frozen in
isopentane cooled in liquid N2 or placed in ice-cold homogenization buffer
for protein or RNA extraction.
Cell cultures
Normal (IMO) and mdx dystrophic (SC5) myoblast cell lines derived from
adult male ‘immorto’ mice were cultured as previously described [3]. Their
myogenic origins were confirmed (Fig. S1A). Myoblast to myotube differ-
entiation (movie S1) was induced by substituting Foetal Bovine Serum (FBS)
with 10% (v/v) HS, removal of -interferon and raising the incubation 
temperature to 37C. J774 cells were maintained as previously described
[7]. Primary cell cultures: freshly dissected soleus muscles from 4-month-
old male C57Bl10 and mdx mice were used as previously described [8, 9]
but with several modifications: cultures of proliferating primary myoblasts
were established in Matrigel-coated cell culture plates (2 mg/ml reduced
growth factor Matrigel; BD Biosciences, Oxford, UK) in a growth medium
containing 20% (v/v) KSR (Knockout Serum Replacement; Invitrogen,
Paisley, UK), 10% (v/v) Donor Horse Serum (Sera Labs, Haywards Heath,
UK) and 2 mM L-glutamine. Contaminating non-muscle cells were removed
by washing isolated fibres in three changes of fresh growth media and then
by pre-plating and agitation to remove the myogenic cells before plating
those on Matrigel. Resulting primary cells were harvested for immunohis-
tochemistry or Western blot analyses.
Antibodies
The following antibodies were used: P2X7-177003, rabbit polyclonal (Synaptic
Systems, Goettingen, Germany), immunohistochemistry (IH) and Western
blotting (WB) at 1:500 dilution; dystrophin: 2166, rabbit polyclonal (gift
from D.J. Blake, Cardiff, UK) IH 1:500; dystrophin: 7A10, mouse mono-
clonal (DSHB) WB 1:100; extracellular signal-regulated kinase (ERK1/2):
9102, rabbit polyclonal (Cell Signalling Tech, Boston, USA) WB 1:2000; P-
ERK1/2: 9106, mouse monoclonal (Cell Signalling Tech) WB 1:1000;
F4/80: 74383, rabbit polyclonal (Abcam, Cambridge, UK) WB 1:500; -
actin: A2066, rabbit polyclonal (Sigma-Aldrich) WB, 1:100.
RT-PCR analysis
Total cellular RNA was extracted from mouse skeletal muscle and mus-
cle cell cultures using Trizol (Sigma-Aldrich) and first strands prepared
using Superscript III first strand synthesis system (ThermoFisher,
Loughborough, UK). Reverse transcriptase was omitted in negative con-
trols. RT-PCRs for specific P2X7(a) and (k) variants were performed indi-
vidually and in multiplex PCR. Exon 1a- and 1k-specific forward primers
(5-CACATGATCGTCTTTTCCTAC-3 and 5-GCCCGTGAGCCACTTATGC-3’,
respectively) were combined with reverse primers in exon 4 (5’-GGTCA-
GAAGAGCACTGTGC-3), exon 5 (CCTTGTCTTGTCATATGGAAC-3) or
exon 7 (5-TCTGTAAAGTTCTCTCCTGC-3). Consistent results were
obtained with different sets of primers. For exons 7–9 splicing the follow-
ing primers were used: forward (e7–8) 5-CTTTACAGAGGTG-
GCAGTTCAGGG-3 or (e7–9) 5-GAGAACTTTACAGAGGTGGCAGTTCA-
GATA-3 with a common reverse primer 5-CGAAGTAGGACAGGGTG-
GATCC-3. PCR conditions were: 94C for 10 sec., 57C for 60 sec., and
72C for 60 sec. followed by 72C for 10 min.
Pannexin 1 primers were: 5-GACTGGAGCTGGCGGTGGACAAGAT and
5-GCGATCGGGGATGGTGCTGTCATTT-3. PCR conditions were: 94C for
10 sec., annealing 60C for 60 sec. and extension 72C for 60 sec. followed
by 72C for 10 min. PCR products were analysed in 2% (w/v) agarose 
gels and visualized using CHEMI GENIUS2 BIO imaging system (Syngene,
Cambridge, UK). PCR conditions and GAPDH controls were as previously
described [3, 10]. The authenticity of PCR products was confirmed by
restriction enzyme analysis or sequencing.
Quantitative (Taq man qPCR) and 
semi-quantitative (sqPCR) analyses
qPCRs were performed using ABI Prism 7700 sequence detection system
(PerkinElmer Life Sciences, Cambridge, UK) with Taqman probes. Relative
expression was calculated as a ratio of P2X7 to GAPDH. Primers
(Mm01199501_m1 to mouse P2X7 exon 3–4 and Mm00440582_m1,
exons 5–6; mouse GAPDH endogenous control; Applied Biosystems)
were used according to manufacturer’s instructions. Semi-quantitative
experiments to compare relative levels of P2X7(a) and P2X7(k) tran-
scripts were performed essentially as previously described [11]. First-
strand dilution series were used and 5 l aliquots of PCR reactions were
removed at cycle 14, 17, 20, 23 and 26 for GAPDH and 26, 29, 32, 35 and
40 for P2X7. PCR products were resolved by agarose gel electrophoresis
and imaged following 2 sec. UV exposure using CHEMI GENIUS2BIO
imaging system (Syngene). Bands representing PCR products were quan-
tified using the integrated pixel density measurement function of ImageJ
software [12]. Integrated densities were plotted against cycle number to
generate PCR profiles using non-linear curve fitting (Microcal Origin 7.0).
Ct values for GAPDH and P2X7 were derived from a standardized baseline
and relative expression calculated as earlier. All experiments were
repeated at least three times and performed in triplicate.
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Cytosolic Ca2 measurements in muscle cell
lines in vitro
SC5 myoblasts were cultured in a 96-well plate for 48 hrs under conditions
described in Materials and Methods. Cells (70–80% confluent) were
loaded with 4 M Fura 2-AM (Invitrogen) in culture medium for 35 min. at
37C in a 95% O2, 5% CO2 atmosphere. After two brief washes in the assay
buffer (132 mM NaCl, 5 mM KCl, 1 mM MgCl2, 0.5 mM Na2HPO4, 1 mM
sodium pyruvate, 5 mM D-glucose and 2 mM CaCl2, 25 mM HEPES, pH
7.4) the plates were placed in the plate reader equipped with two injectors
(POLARstar OPTIMA; BMG Labtech, Aylesbury, UK). Cells were treated
first with 200 nM thapsigargin (Sigma-Aldrich) and then the effects of 1
mM ATP, in the absence or presence of ivermectin (IVM) or antagonists
[13], were measured. Fluorescence was recorded at 510 nm with excita-
tion at 340/380 nm. Each experiment was repeated at least three times.
ERK1/2 phosphorylation assay
Cells were seeded at 50% confluency in 6-well collagen-coated plates
(Greiner) in 2 ml of normal growth medium. After 24 hrs, growth
medium was replaced with low serum medium (0.5%, v/v FBS). Cells
were incubated for a further 24 hrs before application of agonists and
antagonists. Agonists were applied for 10 min., and antagonists, where
used, were applied 10 min. before the addition of agonists. Cells were
lysed and extracted proteins used for immunoblot analysis with specific
anti-p44/42 and anti-phosphop44/42 antibodies, as described later and
in SI files.
Western blotting
Proteins were extracted from adherent cells by scraping into extraction
buffer Complete Lysis-M, 1  Complete Protease Inhibitor Cocktail, 2 
PhosSTOP Phosphatase Inhibitor Cocktail (all Roche, London, UK), 
2 mM sodium orthovanadate (Sigma-Aldrich) and homogenized by pass-
ing 20 times through a 23-gauge  needle. Total proteins from frozen tis-
sues were extracted by crushing samples in liquid nitrogen and further
homogenization in extraction buffer (composition as earlier). All samples
were centrifuged (800  gav for 3 min. at 4C) and protein concentra-
tions determined using the bicinchonic acid assay kit (Sigma-Aldrich).
Twenty micrograms of  protein was mixed with Laemmli buffer at 1:1
(v/v) ratio with 2.5% (v/v) -mercaptoethanol, heated for 5 min. at 95C
and chilled on ice. Samples were separated on 6–12% (w/v) SDS-PAGE
and electroblotted onto Hybond C membranes (Amersham, UK). Blots
were blocked in 5% (w/v) non-fat milk powder in 1 TBST, 0.01% (v/v)
Tween-20 (Sigma-Aldrich) for 1 hr before probing with a primary anti-
body diluted in the same blocking buffer (overnight at 4C or 2 hrs at RT),
then washed (3) with 1 PBST for 10 min. and incubated with the
appropriate horseradish peroxidase-conjugated secondary antibody
(Sigma-Aldrich) for 45 min. Specific protein bands were visualized using
luminol-based substrates (Uptilight US; Cheshire Sciences, Chester, UK)
and images obtained using a G:BOXChemi XT-16 system (Syngene). -
Actin antibody (Sigma-Aldrich) was used as a protein-loading control. All
densitometric analyses of specific protein bands were made using expo-
sure times within the linear range and the integrated density measure-
ment function of ImageJ software [12]. All experiments were repeated at
least three times with similar results obtained throughout.
Protein deglycosylation assay
Protein samples (100 g) were denatured in a buffer (5%, w/v SDS, 0.4M
DTT) for 10 min. at 100C, then samples were deglycosylated in the reac-
tion buffer containing 2500U PNGaseF (New England Biolabs), 0.5M
sodium phosphate, 10% (w/v) NP-40, for 1 hr at 37C. Fifteen micrograms
of digested samples were used for immunoblotting with anti-P2X7 anti-
body, as described earlier.
Analysis of P2X7-dependent pore formation
Mouse myoblasts (SC-5, IMO) or macrophages (J774) were plated onto
six-well plates (Nunc) coated with collagen and grown for 24 hrs. For the
dye uptake assay, cells were incubated in HEPES buffer (composition as
under Ca2 measurements above, with or without addition of 2 mM CaCl2
or with substitution of NaCl by 130 mM K-glutamate) containing 50 M
propidium iodide (PI) or 3 mM Lucifer yellow. Following addition of 
3–10 mM ATP, PI uptake was measured over 30 min. using an LSM 510
Meta microscope (Zeiss, London, UK). Fifty g/ml digitonin was added at
the end of each experiment to non-selectively permeabilize all cells.
Sequential images were taken before addition of ATP, after 30 min. of incu-
bation in the presence/absence of ATP and after addition of digitonin.
Immunostaining
Cultured cells were fixed in 4% (w/v) paraformaldehyde (PFA) in 1
PBS for 15 min. at 4C then endogenous peroxidase activity quenched
in 1% (v/v) H2O2 in methanol for 15 min. on ice. Blocking was carried
out in the appropriate normal serum [10% (v/v) in 1 PBS with 0.1%
(v/v) Triton X-100 for 30 min. at RT] followed by avidin and biotin block-
ing solutions (Vector Laboratories, Peterborough, UK). Samples were
incubated overnight at 4C or at RT for 2 hrs with specific primary anti-
bodies [diluted in 1 PBS with 10% (v/v) normal serum], washed and
incubated with the respective biotinylated secondary antibody [Vector
Laboratories; 1:200 with 2% (v/v) normal serum in 1 PBS] for 45 min.
at RT. Three 5 min. washes in 1 PBST were used between each step.
Staining was visualized using alkaline phosphatase substrate Vectastain®
ABC-AP kit (Vector Laboratories), briefly rinsed in distilled water before
nuclear counterstaining with methyl green (5 min.), then dehydrated and
mounted using DPX.
Histological muscle examinations
Immunolocalization of the revertant fibres was performed on 10-m-thick
muscle cryostat sections with the 2166 dystrophin antibody (1:500) in
PBST containing 2% (v/v) goat serum and visualized via histochemical
detection using Vectastain®ABC-AP kit (Vector Laboratories) as described
earlier. Central nucleation was visualized by methyl green staining. Slides
were dehydrated and mounted using DPX. Muscle section images were
assembled as macro-images (Corel PHOTO-PAINT x3) and enumerations
of revertant and centrally nucleated fibres were obtained via binary label-
based counting using ImageJ Cell Counter Plugin [12]; two cross-sec-
tional areas were assessed per muscle, taken at one third and two thirds
longitudinal position, values were compared with total fibre counts per
cross-section.
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Statistical analysis
Statistical significance of data was assessed using one- or two-way ANOVA
with post-hoc Tukey’s test (Microcal Origin 7.0) or Bonferonni test (Prism
4), respectively. A P-value of 	 0.05 was considered statistically signifi-
cant. Data are reported as mean 
 S.E., where n  3–5 for PCR and
Western data and n  3–9 for histological analyses.
Results
Expression of specific P2X7 mRNA splice 
variants in normal and dystrophic muscles
As the altered responses in dystrophic muscle cells in vitro [3]
could not be explained by differences in the agonist concentra-
tions used, there might be cell type–dependent variation in the
molecular composition of the P2X7 receptor complex. P2X7
mRNA undergoes alternative splicing and splice variants have
been identified for both the human and mouse P2X7, which
significantly alter the receptor function [10, 14]. We have
recently been involved in identification of a novel mouse P2X7
splice variant, P2X7(k), encoding an isoform that forms recep-
tors with higher agonist sensitivity [10]. Therefore, RT-PCR
analysis was performed to identify potential changes in the
expression of specific P2X7 splice variants in dystrophic mus-
cle. We first compared the expression patterns of the main
P2X7(a) and the P2X7(k) variant in normal control (IMO, 
C57-immortalized) and dystrophic (SC5, mdx-immortalized)
myoblast cultures and in normal and mdx adult muscles and
brains. Both transcripts were detected in the IMO and SC5
myoblasts (Fig. 1) and in normal and dystrophic muscles and
brains. Multiplex PCRs performed using both the P2X7(a) and
(k) variant-specific forward primers and a common reverse
primer indicated that there were no significant shifts in expres-
sion patterns or major differences in the relative amount of
these splice variants in normal and dystrophic myoblasts and
tibialis anterior (TA) muscles (Fig. 1B).
Fig. 1 Characterization of P2X7 mRNA
splice variant expressions in normal and
dystrophic tissues. (A) Schematic illustra-
tion of the alternative exon 1 and exons 7–9
splice variants. (B) Representative images
of PCR products visualized in agarose gels
showing expression patterns of P2X7(a)
and P2X7(k) variants in brain and TA mus-
cle and in immortalized myoblasts derived
from normal (C57) and mdx mouse skeletal
muscle. (C) Representative gel images
demonstrating the exons 7–9 splice variant
presence (7–9ss). (D) Plot of qPCR data of
total P2X7 mRNA expression in both wild-
type and mdx immorto and primary
myoblasts and in mdx muscles (TA, GC
soleus and diaphragm) compared with nor-
mal controls (*P 	 0.0001, F  135.39)
and TA of Glaxo P2X7 splice-variant knock-
out mice. Each qPCR was repeated in at
least three different samples and run in trip-
licates. Data were analysed by one-way
ANOVA followed by Tukey’s post-hoc test;
error bars represent S.E.
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Another alternatively spliced variant of the human P2X7 recep-
tor lacking exon 8 and producing an isoforms with deleted C-ter-
minus was shown to act in a dominant negative fashion to disrupt
the normal ATP signalling in cancer cells [15]. We have analysed
expression of a mouse orthologue of this splice variant in
myoblasts and myotubes using primer sets spanning the spliced
region (789) as well as primers specifically targeting the
splice junctions (7/8 and 7/9). We found that this splicing event
does occur in mice. However, the levels of the exons 
7–9 splice variant were very low and there was no significant dif-
ference in its expression in normal versus dystrophic myoblasts
or myotubes (Fig. 1C).
Next, real-time PCR (qPCR) was used to quantify differences in
the relative abundance of the main P2X7 transcripts in dystrophic
and normal muscles (Fig. 1D). Taqman analysis of global P2X7
expression levels in dystrophic and normal muscle showed signif-
icant up-regulation (3- to 14-fold) of this receptor mRNA in both
immortalized and mdx-derived primary myoblasts and in dys-
trophic TA, gastrocnemius (GC), soleus and diaphragm muscles in
situ (Fig. 1D; P 	 0.001). Changes in primary cells and tissues
ruled out the possibility that P2X7 up-regulation was an artefact of
cell immortalization. In initial semi-quantitative experiments,
exons 2–6 amplifications from first-strand dilution series estab-
lished an expected increase in threshold cycle and showed that the
Ct values provide reliable estimates of relative P2X7 mRNA abun-
dance. This was confirmed by using P2X7 splice variant knockout
samples (Fig. 1D). Subsequently, semi-quantitative PCR analyses
with specific primer sets revealed that both P2X7(a) and P2X7(k)
transcripts were up-regulated to similar extents in all but one mdx
muscle groups tested (Fig. 1D). The exception was mdx
diaphragm, where the P2X7(a) increase was not associated with
P2X7(k) variant up-regulation. The results of all qPCRs are sum-
marized in Figure 1D.
P2X7 receptor expression and signalling 
in normal and dystrophic myoblasts
Having shown increased expression of P2X7 transcripts in dys-
trophic cells and tissues, we analysed P2X7 protein levels in
normal and dystrophic samples using Western blotting.
Previous studies have shown that several of the available and
commonly used antibodies are not fully specific to P2X7 pro-
teins [16]. Our own analyses on HEK cells overexpressing P2X7
and in tissues (spleen, salivary glands, lungs, brains, kidneys,
liver and skeletal muscle) from two P2X7 knockout mouse
strains (Glaxo and Pfizer) revealed that, of several antibodies
tested, the C-terminal antibody (Synaptic Systems) gave the
most reproducible results under the conditions described here.
This antibody was also suitable for detecting the main receptor
splice variants [17]. Upon muscle sample separation by SDS-
PAGE and immunoblotting, there was a predominant band at
about 78 kD, the expected molecular mass of the glycosylated
form of the P2X7 subunit (Figs 2A and 3A). Complete deglyco-
sylation with PNGase F reduced the band size to ~65 kD, in good
agreement with the calculated molecular weight of the protein
(Fig. 2B). Bands of identical size and glycosylation patterns
were detected in control protein extracts from HEK cells
expressing mouse P2X7 protein and from dystrophic myoblasts
(Figs 2B and 3A).
Comparison of protein samples from normal and dystrophic
immortalized myoblasts showed a pronounced up-regulation of
P2X7 protein in dystrophic cells (Fig. 3A), which was in agreement
with higher transcript levels found in our qPCR data. Elevated lev-
els of P2X7 receptor protein were also found in dystrophic
myotubes (Fig. 3B).
Again, to exclude the possibility that P2X7 protein up-regulation
was an artefact of cell immortalization, we analysed primary
myoblasts from normal and mdx muscles. The results of these
experiments confirmed a statistically significant (P 	 0.001)
increase in P2X7 protein in primary mdx myoblasts in comparison
with non-dystrophic control (Fig. 3C). Increased P2X7 expression
in primary mdx myoblasts detected by Western blotting correlated
with qPCR (discussed earlier) and immunocytochemistry data
(Fig. S1).
We previously demonstrated a significant increase of P2X7-
mediated Ca2 influx in mdx myoblasts, which was blocked by
two P2X7 receptor antagonists, Coomassie Brilliant Blue G-250
(CBB) and KN-62 [3]. Here, we have extended that study by using
two novel P2X7 receptor antagonists; A740003 and A438079 of
higher sensitivity and selectivity, which completely blocked Ca2
influx in a dose-dependent manner (Fig. 4). In addition to P2X7,
expression of P2X4 receptors has previously been demonstrated
in myoblasts [3] and recent evidence indicates specific structural
Fig.  2 Characterization of P2X7 protein detection specificity. (A)
Representative image of Western blot analysis with P2X7 antibody
(Synaptic Systems) in protein samples from HEK cells overexpressing
P2X7R, in brains and TA muscles from mdx mouse and from two P2X7
knockout strains (Glaxo and Pfizer). Distinct bands of ~78 kD are visible in
protein samples from cells overexpressing P2X7R and in brain and muscle
from mdx mouse but not in knockout samples. The specificity of smaller
bands is unclear. (B) PNGase F deglycosylation reduced the main band size
to ~65 kD in both P2X7R transfected HEK cells and in dystrophic
myoblasts; n  3.
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and functional interactions between P2X7 and P2X4 receptors
[17]. However, pre-incubation of dystrophic myoblasts with 
0.25 M IVM, the allosteric P2X4 receptor modulator [18] did not
potentiate Ca2 responses to ATP (Fig. 4).
Subsequently, we have analysed differences in ERK1/2 phos-
phorylation [19] as a marker of P2X7 signalling cascade inde-
pendent of the Ca2 influx [20]. Western blotting with anti-ERK1/2
(p44/42) and anti-phosphoERK1/2 antibodies showed that dys-
trophic myoblasts responded to ATP with a sustained phosphory-
lation of these ERK proteins. This response was significantly faster
and stronger than in normal myoblasts and showed correlation
with P2X7 up-regulation (Fig. 3A and D). ERK phosphorylation in
dystrophic cells was confirmed to be P2X7 dependent through the
use of specific agonists and antagonists. The P2X7 agonist BzATP
(300 M) mimicked the effects of ATP (Fig. 5A) and a 
10 min. pre-incubation with 1 M CBB blocked the BzATP- and
ATP-induced phospho-ERK response (Fig. 5A). Lower concentra-
tions of ATP (25 M) or pre-incubation of cells with 0.25 M IVM
before exposure to 500 M ATP had no effect on ERK phosphory-
lation in dystrophic myoblasts (Fig. 5A), thus ruling out P2X4
receptors as having a significant role in these responses.
NAD is known to induce an ATP-independent activation of
P2X7 receptors [21] and its effects have not been previously
characterized in mdx muscles. Incubation of dystrophic
myoblasts with 2 M NAD caused a significant but transient ERK
phosphorylation response (Fig. 5B). In contrast, 2 M NAD was
ineffective in control myoblasts or in HEK cells expressing
homomeric P2X7(a) receptors (Fig. 5B).
ATP does not induce cytolytic pore opening 
in dystrophic myoblasts
The sustained activation of P2X7 receptors triggers membrane
permeabilization to large molecules up to 900 Da. We therefore
tested whether or not activation of P2X7 could increase plasma
membrane permeability in dystrophic cells. Initially, PI uptake was
used to monitor ATP-induced large pore formation in proliferating
dystrophic and control myoblasts and in J774 macrophages (pos-
itive control). Maximal cell permeabilization (100% cells) was
measured as the nuclear dye influx following addition of 50 g/ml
digitonin. Addition of ATP triggered cell shape changes (rounding)
in proliferating dystrophic myoblasts but ATP concentrations 
of 3–10 mM did not induce dye uptake into these cells in Ca2-
containing medium, Ca2-free medium or in K-glutamate buffer
(Fig. 6). Similarly, there was no discernible dye uptake into differ-
entiating myoblasts (including C2C12 cells) or into differentiated
myotubes (Fig. S2). In contrast, the same concentrations of ATP
induced strong dye uptake into J774 macrophages (~99% positive
Fig. 3 Analysis of P2X7R protein levels and
ERK activation in normal and dystrophic
muscle cells in vitro. (A) Representative
immunoblots showing relative levels of
phospho-p44/42, p44/42 and P2X7 recep-
tor proteins at specific time-points (0–15
min.) following activation of P2X7R with 1
mM ATP. Top: HEK cells (negative controls)
and HEK overexpressing P2X7 receptor
(positive control); bottom: wild-type and
mdx immorto myoblasts. Specific P2X7
receptor expressions and the extent of the
time-dependent increase in ERK phospho-
rylation are shown. (B) Typical immunoblot
showing P2X7 receptor levels in myotubes
formed by dystrophic and control muscle
cells. (C) Representative Western blot
image of P2X7R levels in primary mdx and
wild-type (C57) myoblasts. (D) Time
course of phospho-p42 ERK induction in
wild-type and mdx immorto myoblasts.
Data from at least three independent exper-
iments were quantified and plotted as
means 
 S.E.M. Statistical analysis per-
formed with ANOVA with post-hoc Tukey’s
test demonstrated a significant effect 
(*P 	 0.001) of cell type.
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cells; Fig. 6). A similar lack of permeabilizing response in dys-
trophic myoblasts was also observed with substitution of PI by the
anionic dye, Lucifer yellow [22] (Fig. 6). The absence of pore
opening was unlikely to be due to a lack of pannexin-1 channels
[23] as RT-PCR amplification using pannexin-1 primers showed
that both normal and dystrophic myoblasts and myotubes express
this transcript, with relative levels being higher in undifferentiated
cells (Fig. S3).
Increased P2X7 receptor expression and 
signalling in normal and dystrophic muscles
To study P2X7 receptor protein in dystrophic muscles in situ, we
performed Western blot analyses in muscle extracts from 4-
month-old wild-type (C57Bl10) and dystrophic mdx mice (Fig. 7A
and B). Densitometric analysis showed significant increases in
P2X7 protein levels in mdx TA, GC, soleus and diaphragm muscles
compared with age-matched wild-type controls (Fig. 7C).
Importantly, concomitant with P2X7 up-regulation, there were sig-
nificantly higher levels of phospho-ERK1/2 found in mdx mice
muscles when compared to control samples (Fig. 7A and D).
At 4 months, inflammatory cell infiltrations in mdx leg muscles
are decreased and thus would not be expected to contribute to
P2X7 receptor levels [24]. However, to exclude the possibility that
P2X7 protein levels were elevated due to its presence on residual
macrophages, the same blots were re-probed with the pan-
macrophage marker F4/80. No significant difference in F4/80
expression was found in mdx compared to wild-type muscle
groups (Fig. 7E).
Muscle analyses following CBB administration 
in mdx mice in vivo
To determine whether purinergic agents may influence the develop-
ment of dystrophic phenotype in vivo, mdx mice were injected
intraperitoneally with the P2X7 antagonist, CBB (125 mg/kg body
weight) every 3 days over the vulnerable period (weeks 3–14) and
analysed at 16 weeks. Control mice received the same volume of
saline solution. Histological sections of TA muscle from these mice
were analysed to determine the extent of central nucleation, total
fibre number and revertant (dystrophin-positive) fibre counts. Both
central nucleation and revertant fibre frequency increased with age,
as expected (Fig. 8). However, there was a statistically significant
decrease in the revertant fibre number in muscles of CBB-injected
mice (Fig. 8), indicating a reduced number of degeneration–regen-
eration cycles [6] occurring in treated animals.
Discussion
ATP is an important extracellular signalling molecule. Although
first indications of functional ATP receptors in skeletal muscle
cells emerged in 1983 [25], understanding of the physiological
roles of these receptors has started to develop only recently. 
We know that extracellular ATP can potentiate excitation by 
acetylcholine at neuromuscular synapses [26, 27] and modulate
Ca2 homeostasis and muscle plasticity [5]. In developing and
regenerating skeletal muscles, ATP acting through two distinct
classes of purinoceptors (P2X ionotropic and P2Y metabotropic
receptors) has a role in myogenesis, satellite cell/myoblast prolif-
eration,  differentiation and motility [28–31], in neuromuscular
junction formation [32, 33] or in muscle regeneration [34]. P2X7
has recently emerged as an important skeletal muscle receptor
with roles in both activation of myoblast proliferation [28] and
myotube formation [30] and in dystrophic pathologies [3, 35].
P2X7 expression and/or function are up-regulated by inflam-
matory mediators and by ATP itself [4] and are markedly increased
in several pathologies [36, 37]. Results of this study demonstrate
P2X7 purinergic alteration in myoblasts, differentiated myotubes
Fig. 4 Characterization of receptors involved in ATP-evoked increases in
[Ca2]c in immortalized mdx myoblasts. Reproducible traces generated by
stimulation with ATP (1 mM) showing the effects of (A) ivermectin (IVM, 0.25
M), A740003 and A438079 (both 100 M). (B) The dose response effects
of 25, 50 and 100 M A740003 on ATP-stimulated responses. Tg is the
effect of thapsigargin (200 nM) pre-treatment used to empty intracellular
Ca2 stores before addition of ATP in Ca2-containing medium. Traces are
representative of three individual experiments conducted in triplicate.
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and in dystrophic mdx muscles in situ where we found both ele-
vated levels of P2X7 mRNA and protein, as well as changes in
receptor functions.
In view of significant differences in ATP sensitivities of
recently discovered P2X7 splice variants, which could explain the
dystrophic phenotype, we have compared these splicing patterns
in normal and dystrophic samples. However, the P2X7(k) higher
sensitivity variant [10] was only a minor P2X7 transcript in mus-
cle cells and its up-regulation in dystrophic muscles (except
diaphragms) mirrored that of the P2X7(a) variant. The mouse
orthologue of a human P2X7 receptor transcript with exon 8
spliced out (and a resulting shift of coding frame) does exist. This
truncated variant was previously found in human cancer cells,
where it may block normal P2X7 functions [15]. However, it was
a low-abundance transcript in muscles and its expression did not
change in dystrophic cells. It would therefore seem unlikely that
Fig. 6 Absence of P2X7 cytolytic pore opening in mdx myoblasts. Propidium iodide (PI) and Lucifer yellow (LY) uptake following 30 min. stimulation with
10 mM ATP. Representative sequential images taken at the beginning of the experiment (unstimulated), after incubation with ATP in the presence of PI or
LY and following total cell membrane permeabilization with digitonin are shown. ATP treatment caused significant PI fluorescence in J774 macrophages
and triggered cell shape changes (rounding) in immortalised mdx myoblasts (SC5) but no PI or Lucifer yellow fluorescence. At least three independent
experiments were performed with cells from three different early passages.
Fig. 5 Characterization of P2X7 receptor
activation in normal and dystrophic
myoblasts. (A) Representative immunoblots
showing changes in ERK phosphorylation
studied using P2X7 agonist/antagonist
combinations: BzATP (300 M) and ATP
(500 M). CBB panels represent the effects
of both agonists applied after10 min. pre-
incubation with 1  M CBB or with CBB
alone (negative control). 0.25 M iver-
mectin was used to study the potential
involvement of P2X4 receptors. (B)
Representative immunoblots of ERK phos-
phorylation triggered by 2 M NAD. Note a
transient ERK phosphorylation (top panels)
in dystrophic myoblasts but not in wild-type
cells (triplicate samples). NAD had no effect
on ERK phosphorylation in HEK cells over-
expressing P2X7R or in HEK controls (bot-
tom right and left panels, respectively).
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differences in the preponderance of these splice variants could
explain the dystrophic P2X7 phenotype.
Stimulation of P2X7 receptors activates various cell signalling
pathways including ERK1/2 phosphorylation and Ca2 fluxes. In dys-
trophic but not control muscle cells, both pathways were activated
and showed specific agonist/antagonist dependencies, confirming
these as being evoked by P2X7 receptor stimulation. The ERK path-
way is known to have dual roles in muscles. It can inhibit differentia-
tion at the onset but also promote fusion at the late stage of muscle
Fig. 7 Analysis of P2X7 expression and activation in mdx and C57 muscles
at 4 month. (A) Immunoblots of dystrophin (Dp427 muscle isoform), P2X7
receptor, ERK and phospho-ERK1/2 in protein extracts from hind limb
muscles [tibialis anterior (TA), gastrocnemius (GC), soleus] and (B) in
diaphragms of 4 month old wild-type and mdx mice. -Actin represents a
control for equal protein loading. Images are representative of at least three
independent experiments. (C, D) Densitometric analyses of immunoblot
results. Two-way ANOVA revealed that for P2X7 protein expression levels,
the main effect of genotype was significant (*P 	 0.0001, F  59.91)
whereas the effect of muscle type was not significant (P  0.05).
Moreover, for phospho-ERK1/2 protein expressed as a percentage of
ERK1/2, the main effects of muscle type and genotype were significant 
(*P  0.0010, F  12.88 and P  0.0007, F  20.15, respectively). (E)
Representative immunoblot analysis of the same set of leg muscle samples
with the F4/80 macrophage marker to evaluate the abundance of
macrophages in dystrophic muscles at 4 months of age.
Fig.  8 Analysis of mdx muscles following CBB administration in vivo.
Relative proportion of centrally nucleated (A) and dystrophin-positive
revertant fibres (B) in TA mdx muscles following treatment with CBB.
There was an expected significant increase in numbers of centrally
nucleated (A) and revertant fibres (B) with age (*P 	 0.05). CBB treat-
ment caused a  statistically significant decrease in numbers of revertant
fibres in 16-week-old mdx mice (*P  0.028, F  5.799); n  5. Data
were analysed using two-way ANOVA with post-hoc Bonferroni test.
Error bars represent S.E. (C) Representative micrographs showing
regions of central nucleation and revertant fibres (dystrophin
immunolocalization; VIP staining) in saline- and CBB-injected animals
(scale bars  60 m).
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differentiation [38–40]. However, ERK phosphorylation can be trig-
gered by a plethora of stimuli [41] and therefore the importance of
P2X7 activation for ERK muscle function is currently not clear.
In addition to the more rapid ERK signalling associated with
the dystrophic phenotype, there is also altered sensitivity to NAD
[21], which confirms that the molecular milieu in which P2X7
 signalling occurs differs between diseased and normal cells.
Further studies should reveal the mechanism(s) linking dystrophin
absence with P2X7 receptor function.
In muscle, as in other cells studied, ATP may have a dual role.
Low, possibly tonic ATP concentrations having a signalling func-
tion leading to cell proliferation, migration or differentiation, while
a sustained stimulation by high ATP concentrations may result in
drastic changes in cellular homeostasis [42, 43].
The intracellular ATP content of muscle is particularly high and
thus large amounts are released into the extracellular space due
to the fragility of dystrophic myofibres. The P2X7 receptor is
 considered a ‘danger’ sensor, detecting ATP released where
 tissue damage occurs [4, 42, 44]. P2X7 activation affects the  
pro-inflammatory pathways [37] and the molecular signature of
dystrophic muscle is dominated by an inflammatory response
[45]. Recent data indeed showed a direct link between inflamma-
tion and P2X7 in dystrophic muscles. Skeletal muscle cells
(myoblasts and myotubes) stimulated with P2X7 agonists
actively participated in inflammasome formation and ASC-1, 
pro-IL-1 and pro-caspase-1 levels were up-regulated in the
muscle tissue of dysferlin-deficient (LGMD-2B) and dystrophin-
deficient mice [35]. In skeletal muscles, growth and regeneration
are regulated by certain inflammatory mediators, for example 
IL-6, IL-4 [46]. Under physiological conditions pro-inflammatory
roles of P2X7 receptors and their effects on muscle growth 
and regeneration might be positively linked but precisely con-
trolled by receptor desensitization and ecto-ATPase activity.
However, these highly regulated effects appear to be dysfunc-
tional in dystrophic muscles.
Interestingly, our data show differences in ATP-evoked P2X7
receptor activation in dystrophic myoblasts. The purinergic phe-
notype occurring in myoblasts is an unexpected finding. This
reflects the prevailing opinion that, because dystrophin protein in
myoblasts is very low or absent, phenotypic consequences of
mutation are unlikely to affect such cells. Contrary to this, Ferrari
et al. (1994) showed that DMD lymphoblasts (cells with
 dystrophin protein also low or absent) are eminently more
 susceptible to ATP damage than their non-dystrophic counter-
parts [47] and we have shown [3] (and here) that myoblasts
derived from the mdx mouse were more susceptible to nucleotide
stimulation and also had abnormal energy metabolism [48]. In
support of these findings, other functions including autonomous
differentiation of dystrophic myoblasts/satellite cells [41] and
dystrophic stem cell loss in early muscle formation [49] have
been documented.
The mechanism(s) of P2X7-induced cell death are not fully
understood and are cell-type dependent. In some cells prolonged
P2X7 stimulation leads to apoptosis, in others it has characteris-
tics of both necrosis and apoptosis. P2X7 receptors can, upon
prolonged stimulation, trigger membrane permeability to large
molecules (	900 Da), which is often a prelude to cell death.
Interestingly, while both Ca2 influx and ERK phosphorylation
were clearly enhanced in dystrophic muscle cells, we were not
able to elicit either cationic or anionic [22] dye uptake (large pore
opening) in these cells, whether as proliferating or differentiating
myoblasts or as myotubes.
It has been suggested that pannexin-1 hemi-channels interact
with P2X7 receptors to form a pore [23]. However, involvement of
pannexin-1 is not always observed or necessary [50], consistent
with our data showing no pore formation even though pannexin-1
transcript was expressed in both myoblasts and myotubes.
Nevertheless, irrespective of the mechanism involved, P2X7
responses may control an intricate equilibrium between cycles of
muscle degeneration and regeneration in mdx mice.
Finally, DMD myotube damage is considered to be the result
of an increased level of [Ca2]i [2]. We found increased
 expression and activity of P2X7 ion channel in dystrophic
myotubes and muscles in situ. Furthermore, ATP-mediated mem-
brane depolarization leads to the secondary modulation of volt-
age-gated Ca2channels while depletion of the internal Ca2
stores would also activate opening of the cell membrane Ca2
channels, according to the store-operated mechanism [42].
Importantly, altered Ca2 influx via L-type, TRP and stretch-acti-
vated channels has been observed in mdx myotubes [51–55] and
medications decreasing [Ca2]i enhance survival of dystrophic
muscles [2,56]. In the light of our data, therapies aimed at
decreasing ATP stimulation should be assessed for potential ben-
efit in DMD. Indeed, suramin (a broad P2 receptor antagonist)
reduced mdx muscle damage [57, 58] and our data show a
decrease of degeneration-regeneration cycles in mdx mice
treated with a specific inhibitor CBB. If the same effects were
found in human muscles this could be an important aspect of the
treatment of this lethal disease.
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